PepGen Inc. (PEPG)

PepGen Inc.'s stock has experienced significant volatility, trending down by 65.22% in the past six months. The stock plummeted approximately 64% due to disappointing Phase 2 clinical trial data from the FREEDOM2-DM1 study of PGN-EDODM1. The U.S. FDA placed a partial clinical hold on the FREEDOM2 trial in the United States, causing the shares to drop by 18-26%. PepGen completed a $100 million public offering to fund ongoing clinical advancement and pipeline development in September 2025.

As a clinical-stage biotechnology company, PepGen Inc. does not have commercialized products or services, and therefore, there is no demand seasonality. The company's performance is driven by clinical trials, regulatory milestones, and funding rounds.

PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurological diseases, utilizing its proprietary Enhanced Delivery Oligonucleotide (EDO) platform to improve drug uptake in key muscle tissues and the central nervous system. Its pipeline includes PGN-EDODM1, in Phase 2 trials for myotonic dystrophy type 1 (DM1), and PGN-EDO51, an investigational candidate for Duchenne muscular dystrophy (DMD).

PepGen Inc. is headquartered in Boston, Massachusetts, United States. Its clinical trials for PGN-EDODM1 have regulatory clearance in the UK, Canada, South Korea, Australia, and New Zealand, despite a partial clinical hold in the U.S.

PepGen Inc.'s brand reputation has been negatively impacted due to setbacks in its clinical development programs and subsequent legal scrutiny. Pomerantz LLP announced an investigation into potential securities fraud claims on behalf of PepGen Inc. shareholders. PepGen discontinued its Duchenne muscular dystrophy (DMD) trials after a Phase 2 trial needed to be paused to review safety data.

PepGen Inc. has a significant number of institutional owners, with 91 institutional owners and shareholders holding a total of 57,280,817 shares. Major institutional owners include RA Capital Management, L.P., Viking Global Investors Lp and Commodore Capital Lp. Notable individual insider holders include James G. McArthur (President and CEO), Kasra Kasraian (Chief Technical Officer) and Joseph Vittiglio (Chief Business & Legal Officer).